Literature DB >> 2254451

A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure.

G C Frazier1, M A Siewertsen, M H Hofker, M G Brubacher, D W Cox.   

Abstract

The most common deficiency allele of the plasma protease inhibitor alpha 1-antitrypsin (alpha 1AT) is PI*Z. Some rare deficiency alleles of alpha 1AT produce low but detectable amounts of plasma alpha 1AT (1-20% of normal), which can be differentiated by isoelectric focusing. Others, designated null (QO) alleles, produce no alpha 1AT detectable by routine quantitative methods. We have previously described a method using DNA polymorphisms, haplotypes, and polyacrylamide isoelectric focusing gels, to differentiate various deficiency alleles. Based on haplotypes, we previously identified, in eight patients, five different null alleles, four of which had been previously sequenced. We have now analyzed all 12 null alleles in these eight patients, using allele-specific oligonucleotide probes, and have identified six different null alleles. We have cloned and sequenced one of these, PI*QOludwigshafen, which has a base substitution in exon II, replacing isoleucine 92 in the normal sequence with an asparagine. This substitution of a polar for a nonpolar amino acid occurs in one of the alpha-helices and is predicted to disrupt the tertiary structure. A total of 13 different alpha 1AT deficiency alleles, 6 of them null alleles, have been sequenced to date.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254451      PMCID: PMC329821          DOI: 10.1172/JCI114919

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Molecular abnormality of human alpha1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency.

Authors:  A Yoshida; J Lieberman; L Gaidulis; C Ewing
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

2.  Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ.

Authors:  J O Jeppsson
Journal:  FEBS Lett       Date:  1976-06-01       Impact factor: 4.124

3.  Molecular characterisation of three alpha-1-antitrypsin deficiency variants: proteinase inhibitor (Pi) nullcardiff (Asp256----Val); PiMmalton (Phe51----deletion) and PiI (Arg39----Cys).

Authors:  A Graham; N A Kalsheker; C R Newton; F J Bamforth; S J Powell; A F Markham
Journal:  Hum Genet       Date:  1989-12       Impact factor: 4.132

4.  Genetic studies on a new deficiency gene (PI*Ztun) at the PI locus.

Authors:  D B Whitehouse; C M Abbott; J U Lovegrove; I McIntosh; C J McMahon; G Mieli-Vergani; A P Mowat; D A Hopkinson
Journal:  J Med Genet       Date:  1989-12       Impact factor: 6.318

5.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

6.  Electroimmuno assay.

Authors:  C B Laurell
Journal:  Scand J Clin Lab Invest Suppl       Date:  1972

7.  Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder.

Authors:  H L Sharp; R A Bridges; W Krivit; E F Freier
Journal:  J Lab Clin Med       Date:  1969-06

8.  Deletion/frameshift mutation in the alpha 1-antitrypsin null allele, PI*QObolton.

Authors:  G C Fraizer; M Siewertsen; T R Harrold; D W Cox
Journal:  Hum Genet       Date:  1989-11       Impact factor: 4.132

9.  Molecular analysis of the gene of the alpha 1-antitrypsin deficiency variant, Mnichinan.

Authors:  E Matsunaga; S Shiokawa; H Nakamura; T Maruyama; K Tsuda; Y Fukumaki
Journal:  Am J Hum Genet       Date:  1990-03       Impact factor: 11.025

10.  Characterization of the intracellular mechanism causing the alpha-1-antitrypsin Nullgranite falls deficiency state.

Authors:  M Holmes; D Curiel; M Brantly; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1989-12
View more
  7 in total

1.  A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis.

Authors:  G E Carpagnano; R Santacroce; G A Palmiotti; A Leccese; E Giuffreda; M Margaglione; M P Foschino Barbaro; S Aliberti; D Lacedonia
Journal:  Lung       Date:  2017-07-01       Impact factor: 2.584

Review 2.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

Review 3.  Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk.

Authors:  D L DeMeo; E K Silverman
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

Review 4.  Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis.

Authors:  Jennifer A Dickens; David A Lomas
Journal:  Drug Des Devel Ther       Date:  2011-08-17       Impact factor: 4.162

5.  Identification and characterisation of eight novel SERPINA1 Null mutations.

Authors:  Ilaria Ferrarotti; Tomás P Carroll; Stefania Ottaviani; Anna M Fra; Geraldine O'Brien; Kevin Molloy; Luciano Corda; Daniela Medicina; David R Curran; Noel G McElvaney; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

6.  A combined in silico and in vitro study on mouse Serpina1a antitrypsin-deficiency mutants.

Authors:  Reto Eggenschwiler; Atanas Patronov; Jan Hegermann; Mariane Fráguas-Eggenschwiler; Guangming Wu; Leon Cortnumme; Matthias Ochs; Iris Antes; Tobias Cantz
Journal:  Sci Rep       Date:  2019-05-16       Impact factor: 4.379

7.  Severe alpha-1 antitrypsin deficiency in composite heterozygotes inheriting a new splicing mutation QOMadrid.

Authors:  Beatriz Lara; Maria Teresa Martínez; Ignacio Blanco; Cristina Hernández-Moro; Eladio A Velasco; Ilaria Ferrarotti; Francisco Rodriguez-Frias; Laura Perez; Irene Vazquez; Javier Alonso; Manuel Posada; Beatriz Martínez-Delgado
Journal:  Respir Res       Date:  2014-10-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.